Fulcrum Therapeutics (NASDAQ: FULC) pre-market stock price soared 48.20% to $13.19 after the company announced positive results from its Phase 1b clinical trial of the sickle cell disease drug pociredir. Data showed that in the 20 mg dosage group, the absolute value of fetal hemoglobin increased by an average of 9.9% by week 6, with 58% of patients reaching hemoglobin levels that could reduce the annual crisis rate by 90%. The drug demonstrated good safety in 148 adult patients. FULC's market capitalization reached $481.7 million, with a one-year stock return of 132.38%.